184 related articles for article (PubMed ID: 24314137)
21. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
22. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
23. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells.
Fulkerson Z; Wu T; Sunkara M; Kooi CV; Morris AJ; Smyth SS
J Biol Chem; 2011 Oct; 286(40):34654-63. PubMed ID: 21832043
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
[TBL] [Abstract][Full Text] [Related]
25. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
[TBL] [Abstract][Full Text] [Related]
28. Identifying Novel ATX Inhibitors via Combinatory Virtual Screening Using Crystallography-Derived Pharmacophore Modelling, Docking Study, and QSAR Analysis.
Ren JX; Zhang RT; Zhang H
Molecules; 2020 Mar; 25(5):. PubMed ID: 32131468
[TBL] [Abstract][Full Text] [Related]
29. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
[TBL] [Abstract][Full Text] [Related]
30. Molecular dynamics simulation of Autotaxin: roles of the nuclease-like domain and the glycan modification.
Koyama M; Nishimasu H; Ishitani R; Nureki O
J Phys Chem B; 2012 Oct; 116(39):11798-808. PubMed ID: 22967301
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
33. Identification of two novel chemical classes of Autotaxin (ATX) inhibitors using Enalos Asclepios KNIME nodes.
Stylianaki EA; Mouchlis VD; Magkrioti C; Papavasileiou KD; Afantitis A; Matralis AN; Aidinis V
Bioorg Med Chem Lett; 2024 May; 103():129690. PubMed ID: 38447786
[TBL] [Abstract][Full Text] [Related]
34. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin.
Jiang G; Madan D; Prestwich GD
Bioorg Med Chem Lett; 2011 Sep; 21(17):5098-101. PubMed ID: 21489790
[TBL] [Abstract][Full Text] [Related]
35. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
36. Structure-function relationships of autotaxin, a secreted lysophospholipase D.
Hausmann J; Perrakis A; Moolenaar WH
Adv Biol Regul; 2013 Jan; 53(1):112-7. PubMed ID: 23069371
[TBL] [Abstract][Full Text] [Related]
37. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
38. "Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.
Stylianaki EA; Magkrioti C; Ladopoulou EM; Papavasileiou KD; Lagarias P; Melagraki G; Samiotaki M; Panayotou G; Dedos SG; Afantitis A; Aidinis V; Matralis AN
Eur J Med Chem; 2023 Mar; 249():115130. PubMed ID: 36702053
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids.
Eymery MC; Nguyen KA; Basu S; Hausmann J; Tran-Nguyen VK; Seidel HP; Gutierrez L; Boumendjel A; McCarthy AA
Eur J Med Chem; 2024 Jan; 263():115944. PubMed ID: 37976710
[TBL] [Abstract][Full Text] [Related]
40. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
